Sequentia spin-out Biotech Tricopharming Research is constituted to commercialize Artennua

Sequentia Biotech has created Biotech Tricopharming Research as a spin-out to commercialise Artennua, an optimized version of Artemisia annua, and the first product to derive from their agropharma R&D department. Sequentia was able to quintuplicate the annual production of the plant, triplicate the foliar biomass and duplicate the concentration of artemisinin in the lab. This year, pilot field studies achieved the critical step of replicating these results, and cultivation of the plant to initiate small-scale production has started at an agrofarm in Tenerife, Canary Islands. Read the press release for the full details!